Neurocrine Biosciences
We're hiring — explore open roles below and apply in a few clicks.
Location
Headquarters: San Diego, California, United States, North America
Region: California
Country: US
Continent: North America
About
Neurocrine Biosciences is a biopharmaceutical company focused on discovering, developing, and commercializing therapies for neurological, neuroendocrine, and neuropsychiatric disorders. With a heritage of scientific founders, the company emphasizes long-term research and clinical development to address significant unmet medical needs and rare diseases. Its work spans early discovery through clinical studies, aiming to bring safe and effective medicines to patients worldwide. Headquartered in the United States, Neurocrine emphasizes brave science and patient-centered outcomes across its therapeutic areas.
Neurocrine Biosciences is a biopharmaceutical company that discovers, develops, and commercializes therapies for neurological, neuroendocrine, and neuropsychiatric disorders. The company serves patients with conditions such as tardive dyskinesia, Huntington’s disease, endometriosis, and congenital adrenal hyperplasia. Its portfolio includes FDA-approved treatments like Ingrezza and ORILISSA.
Neurocrine Biosciences, Inc.
1992
for_profit
active
Industries
Primary Industry: Business Services
Categories
Funding & Financials
Public Company
46800000
over-1b
ipo
NASDAQ:NBIX
nasdaq
Investors
Founders
Errol De Souza
Larry Bock
Wylie Vale
Leadership
Technology Stack
Products
INGREZZA (valbenazine) Capsules: A medication for treating movement disorders such as tardive dyskinesia and chorea associated with Huntington's disease.
CRENESSITY (crinecerfont): A treatment for classic congenital adrenal hyperplasia that helps regulate hormone production and glucocorticoid dosing.
valbenazine (VMAT2 Inhibitor): An investigational drug targeting dyskinetic cerebral palsy by modulating neurotransmitter activity to control involuntary movements.
osavampator/NBI-1065845 (AMPA receptor modulator): A drug candidate in development for adults with major depressive disorder who have an inadequate response to current treatments.
NBI-568 (M4 Agonist): A drug candidate in phase 3 development for treating schizophrenia by targeting M4 muscarinic receptors to modulate neural pathways.
NBI-770 (NMDA NR2B Negative Allosteric Modulator): A phase 2 investigational drug for major depressive disorder that modulates NMDA receptor activity to affect mood regulation.
Funding rounds
POST_IPO_EQUITY · 10000000 · (2009-12-01T00:00:00)
